BALB/c-Il10 KO Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
BALB/c-Il10 KO Mouse
Product Name
BALB/c-Il10 KO Mouse
Product ID
C001527
Strain Name
BALB/cAnCya-Il10em1/Cya
Backgroud
BALB/cAnCya
When using this mouse strain in a publication, please cite “BALB/c-Il10 KO Mouse (Catalog C001527) were purchased from Cyagen.”
Disease Animal Models
Inflammatory Bowel Disease
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Disease Animal Models
Inflammatory Bowel Disease
Basic Information
Validation Data
Related Resource
Basic Information
Gene Name
Gene Alias
CSIF, If2a, Il-10
NCBI ID
Chromosome
Chr 1
MGI ID
Datasheet
Strain Description
Interleukin-10 (IL-10) is a cytokine secreted by activated T cells, monocytes, B cells, and macrophages, among other antigen-presenting cells. It exhibits broad biological activity. In immune regulation and inflammatory responses, IL-10 can reduce the expression of Th1 cytokines, MHC-II antigens, or co-stimulatory molecules. Simultaneously, it enhances B cell survival, proliferation, and antibody production. Both overexpression (as seen in systemic lupus erythematosus and tuberculosis) and deficiency (as observed in inflammatory bowel disease, psoriasis, asthma, and rheumatoid arthritis) of IL-10 have pathological and physiological significance. IL-10 is a critical susceptibility gene for inflammatory bowel disease (IBD), and its functional defects play a central role in the development of ulcerative colitis (UC)-type IBD [1]. The genetic polymorphism of IL-10 may also contribute to the occurrence of UC-type IBD or Crohn’s disease (CD)-type IBD [2]. Therefore, IL-10 gene knockout mice exhibit a phenotype similar to human inflammatory bowel disease (IBD) and are widely used in research related to relevant diseases [3].
During the gene editing process, using different mouse strain backgrounds may lead to differences in disease phenotypes. BALB/c strain and C57BL/6 strain exhibit significant differences in susceptibility to infection, resistance, and immune deficiencies. For specific applications such as evaluating antifungal drug efficacy, cancer treatment, and immunological research, the BALB/c strain has its unique advantages [4-6]. Research has found that IL-10-deficient BALB/c mice are more susceptible to colitis than mice of the C57BL/6 strain. Additionally, the disease phenotype is more severe in IL-10-deficient BALB/c mice, making them a more effective model for simulating the disease progression of human colitis [7].
This model is Il10 gene knockout mice, where the Il10 gene homologous to the human IL10 gene has been knocked out in BALB/cAnCya mice. Homozygous BALB/c-Il10 KO mice are viable and fertile. At 8 to 9 weeks of age, BALB/c-Il10 KO mice spontaneously develop colitis symptoms, characterized by weight loss, reduced survival rates, elevated levels of inflammatory factors, and abnormalities in intestinal inflammation and phenotype. BALB/c-Il10 KO mice can be used for research related to Crohn’s disease (CD), colitis, other inflammatory bowel diseases (IBD), cancer, congenital and adaptive immune disorders, as well as various inflammation or autoimmune conditions. It should be noted that due to individual variability and environmental factors, the disease presentation of this model may vary. The data in this manual are based on internal facility observations and are provided for reference. Actual disease presentation may vary; please use the mice according to your specific experimental conditions for best results.
Reference
Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH; IBSEN study group; Mathew CG, Schreiber S. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet. 2008 Nov;40(11):1319-23.
Zhu L, Shi T, Zhong C, Wang Y, Chang M, Liu X. IL-10 and IL-10 Receptor Mutations in Very Early Onset Inflammatory Bowel Disease. Gastroenterology Res. 2017 Apr;10(2):65-69.
Kiesler P, Fuss IJ, Strober W. Experimental Models of Inflammatory Bowel Diseases. Cell Mol Gastroenterol Hepatol. 2015 Mar 1;1(2):154-170.
Roque S, Nobrega C, Appelberg R, Correia-Neves M. IL-10 underlies distinct susceptibility of BALB/c and C57BL/6 mice to Mycobacterium avium infection and influences efficacy of antibiotic therapy. J Immunol. 2007 Jun 15;178(12):8028-35.
Howes A, Taubert C, Blankley S, Spink N, Wu X, Graham CM, Zhao J, Saraiva M, Ricciardi-Castagnoli P, Bancroft GJ, O'Garra A. Differential Production of Type I IFN Determines the Reciprocal Levels of IL-10 and Proinflammatory Cytokines Produced by C57BL/6 and BALB/c Macrophages. J Immunol. 2016 Oct 1;197(7):2838-53.
Tan GG, Liu Y, Sivalingam SP, Sim SH, Wang D, Paucod JC, Gauthier Y, Ooi EE. Burkholderia pseudomallei aerosol infection results in differential inflammatory responses in BALB/c and C57Bl/6 mice. J Med Microbiol. 2008 Apr;57(Pt 4):508-515.
Berg DJ, Davidson N, Kühn R, Müller W, Menon S, Holland G, Thompson-Snipes L, Leach MW, Rennick D. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest. 1996 Aug 15;98(4):1010-20.
Strain Strategy
The Il10 gene is located on mouse chromosome 1 and exons 1-5 were knocked out by gene editing techniques.

Figure 1. Diagram of the gene editing strategy for the generation of BALB/c-Il10 KO mice.
Application Area
Research on inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and colitis;
Research on cancer, congenital and adaptive immune disorders, and other inflammatory or autoimmune conditions.
Validation Data
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
